title: What do we know about the ocular adverse effects associated with intravenous bisphosphonates?
authors.forename: O Sahap
authors.initials: OS
authors.lastname: Atik
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005128:Eye Diseases / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D007262:Infusions, Intravenous; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid